Abstract
Objective To investigate the role of perioperative antiviral therapy with Entecavir for patients with hepatitis B virus related hepatocellular carcinoma (HBV-HCC) with low serum HBV DNA levels. Methods The HVB-HCC patients were randomly divided into 2 groups. Patients in the antiviral group received Entecavir 4 days before hepatic resection while patients in the control group received no antiviral treatment. The serum HBV DNA, liver function, morbidity and length of hospital stay were compared between the two groups. Results Sixteen patients in the control group (n=44) developed HBV reactivation. On the other hand, only 1 patient in the antiviral group (n=44) developed HBV reactivation. Recovery in liver function in the antiviral group was much faster than the control group, especially for glutamic-pyruvic transaminase level. The antiviral group had significantly lower morbidity and shorter total or postoperative hospitalization (all P<0.05). Conclusions Patients with HBV-HCC with low levels of HBV DNA have a high risk of developing HBV reactivation in the perioperative period. Perioperative antiviral therapy was safe and efficacious in preventing HBV reactivation, improved liver function, reduced postoperative complications and shortened hospitalization. Key words: Hepatitis B; Hepatocellular carcinoma; Antiviral therapy; Perioperative period
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
